Vanda Pharmaceuticals (NASDAQ:VNDA) Announces Earnings Results, Beats Estimates By $0.31 EPS

Key Points

• Vanda Pharmaceuticals beat quarterly EPS estimates, reporting a loss of $0.37 per share versus the expected loss of $0.68.
• Third-quarter revenue reportedly rose 24% year over year to $69.8 million, driven by FANAPT growth, favorable HETLIOZ shipment timing, and early NEREUS sales. The company expects to launch BYSANTI in Q4 2026 and could launch Quimilza in the first half of 2027.
• Financial risks remain significant: cash fell to $140.5 million, 2026 cash burn is expected to exceed 2025 levels, and HETLIOZ faces generic competition while NEREUS revenue is expected to remain below $10 million in 2026.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.31, FiscalAI reports. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. The business had revenue of $1.61 million during the quarter, compared to the consensus estimate of $69.20 million.

Here are the key takeaways from Vanda Pharmaceuticals' conference call:

• Third-quarter revenue rose 24% year over year to $69.8 million, driven by continued FANAPT growth, favorable HETLIOZ shipment timing, and early NEREUS sales. FANAPT prescriptions increased 25% year over year, while NEREUS prescriptions and unique prescribers each more than doubled sequentially.
• Vanda expects to launch BYSANTI in the fourth quarter of 2026, with commercial supplies nearly ready, and is preparing for a potential Quimilza launch in the first half of 2027 if the FDA approves its GPP application by the December 12 PDUFA date.
• Positive Phase III results could expand NEREUS into prevention of GLP-1-associated vomiting and HETLIOZ into delayed sleep-wake phase disorder. Management plans to discuss both programs with the FDA and pursue supplemental applications.
• Operating expenses declined 18% sequentially to $93.3 million as major development and launch-preparation activities concluded, and management expects further reductions in coming quarters.
• Vanda ended September with $140.5 million in cash, down $123.4 million from year-end 2025, and expects 2026 cash burn to exceed 2025 levels. HETLIOZ revenue remains vulnerable to generic competition and specialty-pharmacy inventory normalization, while NEREUS 2026 revenue is expected to remain below $10 million.

Vanda Pharmaceuticals Stock Performance

VNDA stock traded up $0.01 during midday trading on Wednesday, hitting $4.00. The stock had a trading volume of 1,996,913 shares, compared to its average volume of 1,491,518. The firm has a market capitalization of $241.85 million, a price-to-earnings ratio of -0.86 and a beta of 0.69. Vanda Pharmaceuticals has a 52 week low of $3.79 and a 52 week high of $9.94. The stock has a 50-day simple moving average of $4.88 and a 200 day simple moving average of $6.27. The company has a current ratio of 1.61, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on VNDA shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a research report on Thursday, October 15th. Oppenheimer initiated coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, September 23rd. They set an "outperform" rating and a $10.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Vanda Pharmaceuticals in a research note on Monday, October 5th. B. Riley Financial reissued a "buy" rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Finally, Zacks Research lowered shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 6th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, Vanda Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $13.08.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda's marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.